Breast-Conserving Therapy for Triple-Negative Breast Cancer
|
|
- Janis Neal
- 6 years ago
- Views:
Transcription
1 Research Original Investigation PACIFIC COAST SURGICAL ASSOCIATION Breast-Conserving Therapy for Triple-Negative Breast Cancer Alexandra Gangi, MD; Alice Chung, MD; James Mirocha, MS; Douglas Z. Liou, MD; Trista Leong, MA; Armando E. Giuliano, MD IMPORTANCE The aggressive triple-negative phenotype of breast cancer (negative for estrogen and progesterone receptors and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2] [formerly human epidermal growth factor receptor 2 (HER2)]) is considered by some investigators to be a relative contraindication to breast-conserving therapy. OBJECTIVES To compare outcomes of breast-conserving therapy for patients with triple-negative breast cancer () with those of patients with the luminal A, luminal B, and ERBB2 subtypes. DESIGN, SETTING, AND PARTICIPANTS Prospective database review at an academic tertiary medical center with a designated breast cancer center. We included 181 consecutive patients ages 29 to 8 years with stages I to III invasive breast cancer who underwent breast-conserving therapy at a single institution from January 1, 2, through May 3, 212. Of these patients, 234 (12.6%) had ; 1341 (72.4%), luminal A subtype; 212 (11.%), luminal B subtype; and 64 (3.%), ERBB2-enriched subtype. EXPOSURE Breast-conserving therapy. MAIN OUTCOMES AND MEASURES The primary outcome measure was local recurrence (LR). Secondary outcome measures included regional recurrence, distant recurrence, and overall survival. RESULTS Triple-negative breast cancer was associated with younger age at diagnosis (6 vs years; P =.1), larger tumors (2.1 vs 1.8 cm; P <.1), more stage II vs I cancer (42.1% vs 33.6%; P =.), and more G3 tumors (86.4% vs 28.4%; P <.1) compared with the non- subtypes. Multivariable analysis showed that did not have a significantly increased risk of LR compared with the luminal A (hazard ratio, 1.4 [9% CI,.6-3.3]; P =.43), luminal B (1.6 [.-.2]; P =.43), and ERBB2 (1.1 [.2-.2]; P =.87) subtypes. Only tumor size was a significant predictor of LR (hazard ratio, 4.7 [9% CI, ]; P =.6). Predictors of worse overall survival included tumor size, grade, and stage and subtype. CONCLUSIONS AND RELEVANCE Breast-conserving therapy for is not associated with increased LR compared with non- subtypes. However, the phenotype correlates with worse overall survival. Breast-conserving therapy is appropriate for patients with. JAMA Surg. 214;149(3): doi:1.1/jamasurg Published online January 1, 214. Author Affiliations: Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California (Gangi, Chung, Liou, Giuliano); Department of Biostatistics, Cedars-Sinai Medical Center, Los Angeles, California (Mirocha); Department of Health Information, Cedars-Sinai Medical Center, Los Angeles, California (Leong). Corresponding Author: Armando E. Giuliano, MD, Department of Surgery, Cedars-Sinai Medical Center, 31 N San Vicente Blvd, Ste 311, Los Angeles, CA 948 (armando.giuliano@cshs.org). 22 jamasurgery.com
2 Breast-Conserving Therapy for Original Investigation Research Breast cancers are characterized by a wide spectrum of clinical, pathologic, and molecular features. Various well-established tumor markers have been used to determine prognosis and response to therapy, including molecular biomarkers allowing for the identification of distinct subtypes of breast cancer. The most common and useful classification is based on the expression of estrogen receptors (ERs), progesterone receptors (PRs), and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) (formerly human epidermal growth factor receptor 2 [HER2]). 1-4 Triple-negative breast cancers (s) are those that lack or only minimally express ERs, PRs, and ERBB2. Triplenegative breast cancers account for approximately 1% to 2% of newly diagnosed breast cancers and tend to exhibit a more aggressive clinical behavior, a metastatic pattern, and poor prognosis compared with other subtypes.,6 Although targeted therapies have been developed for tumors that express ERs, PRs, or ERBB2, treatment for tumors that lack these markers remains challenging. The lack of targeted therapy and the aggressive nature of s have resulted in controversy as to whether breastconserving therapy (BCT) is appropriate treatment for these tumors. Several large randomized clinical trials demonstrate equivalent overall survival (OS) for patients undergoing mastectomy compared with those undergoing BCT; however, none included an analysis of molecular subtypes or. 7,8 For patients with who undergo BCT, many investigators suggest that local recurrence (LR), regional recurrence (RR), and distant metastasis are increased and that OS is decreased compared with the outcomes of patients with non- subtypes Given the aggressive nature of, one can reasonably question whether BCT is appropriate. The purpose of this study was to compare outcomes between patients with and non- who underwent BCT to determine whether LR is increased in patients. Methods This study was performed with the approval of the institutional review board of Cedars-Sinai Medical Center. Informed consent was waived for this retrospective review of a prospective database. We reviewed a prospectively maintained database of patients undergoing evaluation and treatment for breast cancer from January 1, 2, through May 3, 212. Women ages 18 through 8 years with newly diagnosed stages I through III breast cancer were identified. Approximately 2 surgeons performed the procedures that qualified for inclusion in this study. The surgeons did not follow a standardized surgical management protocol. Men, patients undergoing neoadjuvant chemotherapy or mastectomy, and patients with fewer than 9 days of follow-up were excluded from the study. In addition, patients with positive margins were excluded. Most surgeons considered margins to be negative if the tumor-free margin was larger than 1 mm; some surgeons were content if no tumor cells were found at the ink of the surgical specimen on pathologic review. Of the remaining patients, we included only those for whom ER, PR, and ERBB2 status were available. We identified a total study sample of 181 patients. Patients were then categorized according to tumor phenotypic subtype using the presence or absence of tumor markers. Specifically, tumors were classified into luminal A (positive for ER or PR and negative for ERBB2), luminal B (positive for ER or PR and ERBB2), ERBB2 (negative for ER and PR and positive for ERBB2), and (negative for all 3 markers) subtypes based on immunohistochemical identification of these markers on biopsied or excised specimens. A positive ERBB2 marker was defined as immunohistochemical identification (ERBB2 receptor protein on the surface of cells in the breast cancer tissue sample) of 3+ and/or amplified (ratio, >2.) expression of ERBB2 on fluorescence in situ hybridization. Patient and tumor characteristics examined included age at diagnosis, tumor size, histologic subtype, grade, stage, lymph node status, adjuvant systemic treatment, and adjuvant radiotherapy. As is standard practice, conventional whole-breast radiotherapy with opposing tangents was used in nearly all patients. Most patients with invasive cancer at our institution receive a boost dose of radiotherapy to the primary site. The primary outcome measure was LR. Secondary outcome measures included RR, distant recurrence (DR), and OS. As is standard practice, most of the patients were followed up with biannual mammography for 2 years and then annual mammography and physical examination thereafter. Time to recurrence was calculated from the date of diagnosis to the date of recurrence. Survival was calculated from the date of diagnosis to the date of death or the most recent follow-up for surviving patients. Differences on normally distributed variables across the 4 cancer subtypes were assessed by analysis of variance and Tukey post hoc tests. Differences on nonnormally distributed numerical variables across the 4 subtypes were assessed by the Kruskal-Wallis test and Wilcoxon rank sum post hoc tests. Differences between and non- on normally distributed variables were assessed by the independentsamples t test. Differences between and non- on nonnormally distributed numerical variables were assessed by the Wilcoxon rank sum test. Differences on dichotomous variables were assessed by the χ 2 test or the Fisher exact test, as appropriate. Overall survival and freedom from recurrence were estimated by the Kaplan-Meier method and compared across groups by the log-rank test. Hazard ratios (HRs) and their 9% confidence intervals were estimated using Cox proportional hazards regression models. Multivariable Cox models were used to estimate the association of with the risk of death and recurrence, adjusting for potentially confounding variables. Time to recurrence for the Cox models was truncated at years. Candidate predictors in the Cox models for recurrence were age (<, to <, and years), tumor size (<2, 2 to <, and cm), stage, and grade. Subtype (comparing with each other subtype) was the main predictor of interest. A preliminary Cox survival model revealed a very large HR for patients years or older vs those younger than years (HR, 7. [9% CI, ]). Thus, separate multivariable Cox survival models were estimated in patients younger than years and years or older. Candidate predictors in the Cox survival model for patients younger than years were age (< jamasurgery.com JAMA Surgery March 214 Volume 149, Number 3 23
3 Research Original Investigation Breast-Conserving Therapy for Table 1. Patient and Tumor Characteristics Subtype a P Value Characteristic (n = 234) [12.6%] (n = 1341) [72.4%] (n = 212) [11.%] ERBB2 Enriched (n = 64) [3.%] All vs Non- Age at diagnosis, mean (SD), y 6.1 (14.).2 (12.) 6.9 (12.7) 6.2 (12.4) <.1.1 Tumor size, median (range), cm 1.9 (.2-9.) 1. (.1-16) 1.7 (.1-8.) 1.8 (.2-9.4) <.1 <.1 Size distribution, No. (%) T1 (2. cm) 121 (1.9) 897 (66.9) 127 (9.9) 36 (6.3) T2 (>2. to 4.9 cm) 13 (44.2) 2 (3.) 78 (36.8) 26 (.6) <.1 <.1 T3 (. cm) 9 (3.9) 42 (3.1) 7 (3.3) 2 (3.1) Histology, No. (%) Ductal only 218 (93.2) 18 (79.) 188 (88.7) 61 (9.3) Lobular only 2 (.9) 12 (9.) 6 (2.8) Ductal and lobular 7 (3.) 18 (11.8) 16 (7.) 3 (4.7) <.1 <.1 Unknown/other 7 (3.) 4 (.3) 2 (.9) Pathologic stage, No. (%) I 12 (1.3) 81 (63.) 118 (.7) 33 (1.6) II 98 (41.9) 439 (32.7) 77 (36.3) 27 (42.2) <.1 <.1 III 16 (6.8) 1 (3.8) 17 (8.) 4 (6.3) Grade, No. (%) G1 (2.1) 387 (28.9) 24 (11.3) G2 21 (9.1) 629 (46.9) 77 (36.3) 8 (12.) G3 22 (86.3) 299 (22.3) 11 (1.9) 3 (82.8) <.1 <.1 Unknown 6 (2.6) 26 (1.9) 1 (.) 3 (4.7) Lymph node status, No. positive/total No. 67/22 (3.) 3/123 (24.3) 9/194 (3.4) 21/ (3.).4.1 dissected (%) Treatment, No. receiving/no. eligible (%) Adjuvant chemotherapy 183/214 (8.) 44/1164 (38.2) 124/19 (6.3) 1/ (8.) <.1 <.1 Radiotherapy 21/213 (94.4) 1/1116 (9.) 16/18 (89.2) 48/3 (9.6).26.48, triple-negative breast cancer. Not all categories total numbers in column headings owing to missing data. Percentages have been rounded and may not sum to. and years), tumor size, stage, and grade; candidate predictors in the Cox survival model for the group years or older were age (numerical), tumor size, stage, and grade. Subtype (comparing with each other subtype) was the main predictor of interest in both age models. We used a 2-sided. significance level throughout. Analyses were performed with commercially available statistical software (SAS, version 9.2; SAS Institute, Inc). Results We identified 181 patients who received BCT and had complete data for ER, PR, and ERBB2 status. Tumors in 234 patients (12.6%) were ; 1341 (72.4%), luminal A subtype; 212 (11.%), luminal B subtype; and 64 (3.%), ERBB2-enriched subtype. All patients were followed up for at least 9 days after diagnosis, with a median follow-up of (interquartile range, 33-98) months. Patient demographic and tumor data are reported in Table 1. Most of the patients were years or older (74.7%), with the mean age slightly higher in the luminal A group (.2 years) compared with the luminal B (6.9 years), (6.1 years), and ERBB2 (6.2 years) groups (P <.1). All patients had stage I (1122 [.6%]), stage II (641 [34.6%]), or stage III (91 [4.9%]) disease at presentation. Among the 4 subtypes, we found a substantial difference in tumor size (P <.1), histopathologic type (P <.1), pathologic grade (P <.1), and stage (P <.1). When compared with non- patients, patients were younger at diagnosis (mean [SD] age, 6.1 [14.] vs 9.6 [12.6] years; P =.1) and had a larger tumor size (2.1 [1.3] vs 1.8 [1.3] cm; P <.1). In addition, s were more frequently high grade (P <.1), were stage II or III vs stage I (P <.1), and had predominantly infiltrating ductal histologic type tumors (P <.1). Overall, 26.2% of patients had node-positive disease. Of the subtypes, ERBB2 had the strongest association with nodal positivity (3.%) compared with (3.%) or the luminal A (24.3%) or luminal B (3.4%) subtypes (P =.4). When comparing with non- patients, lymph node positivity was not significantly different (3.% vs 2.%; P =.1). Patients were treated with adjuvant systemic therapy and/or radiotherapy. Overall, 49.3% of patients received chemotherapy, whereas 91.2% received radiotherapy. Patients with (8.%) and the ERBB2 subtype (8.%) were more likely to receive chemotherapy compared with patients with the lu- 24 JAMA Surgery March 214 Volume 149, Number 3 jamasurgery.com
4 Breast-Conserving Therapy for Original Investigation Research Figure 1. Kaplan-Meier Estimates of Freedom From Local Recurrence Figure 2. Kaplan-Meier Estimates of Freedom From Regional Recurrence Log-rank P =.13 Log-rank P < receptor 2 [HER2]);, triple-negative breast cancer. Cancer subtypes are receptor 2 [HER2]);, triple-negative breast cancer. Cancer subtypes are Table 2. Multivariable Hazard Model for Local Recurrence at Years a Grade 2 vs (.-6.3).41 Grade 3 vs ( ).6 T2 vs T1 1.6 (.8-3.2).2 T3 vs T1 4.7 ( ).6 vs luminal A 1.4 (.6-3.3).43 vs luminal B 1.6 (.-.2).43 vs 1.1 (.3-.2).87 HR, hazard ratio;, triple-negative breast cancer. minal B (6.3%) and especially the luminal A (38.2%) subtypes (P <.1). A total of 143 (8.8%) patients did not receive radiotherapy. Of these, 12 patients had and 16 had luminal A, 2 had luminal B, and had ERBB2 tumor subtypes. Within the group, 8 patients had comorbid conditions that precluded them from receiving radiotherapy, and 4 patients refused radiotherapy although it was recommended. Within the luminal A and B groups, patients had smaller tumors and were generally older with comorbid conditions and therefore did not receive radiotherapy. Within the ERBB2 group, 2 patients refused the treatment; 3 had significant comorbidities, and although radiotherapy was recommended, they declined. Most of the patients in all groups received adjuvant whole-breast radiotherapy or accelerated partialbreast radiotherapy (94.1% vs 3.8%). Forty-six LRs were observed among the entire study population, including 11 (4.7%) in the group, 8 (12.%) in the ERBB2 group, 23 (1.7%) in the luminal A group, and 4 (1.9%) in the luminal B group. Kaplan-Meier estimated freedom from LR at years was 93% for the, 96% for ERBB2, 9% for luminal A, and 96% for luminal B (P =.13) groups. Figure 1 shows Kaplan-Meier curves for LR for Table 3. Multivariable Cox Model for Regional Recurrence at Years a Stage II vs I.2 ( ).4 Stage III vs I 8.3 ( ).6 vs luminal A 1.3 (.4-4.9).68 vs luminal B.4 (.1-1.8).2 vs.2 (.-.7).2 HR, hazard ratio;, triple-negative breast cancer. patients who underwent BCT stratified by subtype. On multivariable analysis for LR, did not have a significantly increased risk compared with the luminal A (HR, 1.4 [9% CI,.6-3.3]; P =.43), the luminal B (1.6 [.-.2]; P =.43), or the ERBB2 (1.1 [.3-.2]; P =.87) subtype. Based on multivariable analysis, larger size T3 vs T1 classification (HR, 4.7 [9% CI, ]; P =.6) was the only significant independent predictor of LR (Table 2). We observed a total of 21 RRs, including 3 (1.3%) in the, 4 (6.3%) in the ERBB2, 9 (.7%) in the luminal A, and (2.4%) in the luminal B groups. Kaplan-Meier estimated freedom from RR at years was 98% for the, 84% for the ERBB2, 98% for the luminal A, and 96% for the luminal B groups (P <.1) (Figure 2). Multivariable analysis revealed that stage II vs I (HR,.2 [9% CI, ]; P =.4) and stage III vs I (8.3 [ ]; P =.6) were significant predictors of RR (Table 3). Also, was protective for risk of RR, compared with the ERBB2 subtype (HR,.2 [9% CI,.-.7]; P =.2). Distant recurrences were the most frequent recurrences seen among all patients, with a total of 66 patients presenting with metastatic disease after BCT. Of these, 21 (9.%) were in the group, (7.8%) in the ERBB2 group, 31 (2.3%) in the luminal A group, and 9 (4.2%) in the luminal B jamasurgery.com JAMA Surgery March 214 Volume 149, Number 3 2
5 Research Original Investigation Breast-Conserving Therapy for Figure 3. Kaplan-Meier Estimates of Freedom From Distant Recurrence 2 Log-rank P < receptor 2 [HER2]);, triple-negative breast cancer. Cancer subtypes are Table 4. Multivariable Hazard Model for Distant Recurrence at Years a Stage II vs I 1.8 (.8-3.9).16 Stage III vs I.4 ( ) <.1 T2 vs T1 3. ( ).1 T3 vs T1. (2.-1.6).1 G3 vs G1 and G2 1. (.8-2.9).18 vs luminal A 2. ( ).1 vs luminal B 1.6 (.7-3.6).22 vs.8 (.3-2.2).67 HR, hazard ratio;, triple-negative breast cancer. group. Kaplan-Meier estimated freedom from DR at years was 8% for the, 88% for the ERBB2, 9% for luminal A, and 92% for luminal B (P <.1) groups (Figure 3). A more advanced stage (III vs I; HR,.4 [9% CI, ]; P <.1) and larger tumor (T3 vs T1,. [2.-1.6]; P =.1) were associated with an increased risk of DR (Table 4). Among subtypes, patients were at increased risk for DR compared with patients with the luminal A subtype (HR, 2. [9% CI, ]; P =.1) but not those with the luminal B or ERBB2 subtypes. A total of 113 deaths occurred. Patients older than years were excluded from the multivariable analysis of OS because of their higher risk of death (HR, 7. [9% CI, ]). Predictors of worse OS included being years or older vs younger than years (HR, 2.2 [9% CI, ]; P =.), stage III vs I disease (2.8 [1.3-6.]; P =.7), T2 vs T1 classification (1.9 [ ]; P =.3), and T3 vs T1 classification (4.2 [ ]; P =.1). Furthermore, was associated with worse OS compared with the luminal A (HR, 3. [9% CI, ]; P <.1) and luminal B (3.7 [ ]; P =.1) subtypes (Table ). Kaplan-Meier analysis of OS is shown in Figure 4. Table. Multivariable Hazard Model for Overall Survival at Years a Age vs < y 2.2 ( ). Stage II vs I 1.2 (.7-2.1).3 Stage III vs I 2.8 (1.3-6.).7 T2 vs T1 1.9 ( ).3 T3 vs T1 4.2 ( ).1 vs luminal A 3. (2.2-.7) <.1 vs luminal B 3.7 ( ).1 vs 1.3 (.6-3.). HR, hazard ratio;, triple-negative breast cancer. Figure 4. Kaplan-Meier Estimates of Overall Survival Discussion Log-rank P <.1 receptor 2 [HER2]);, triple-negative breast cancer. Cancer subtypes are Breast cancer subtypes are known to have phenotypic diversity with regard to tumor aggressiveness and response to therapy. 3 Triple-negative breast cancer specifically is challenging to treat because it lacks a targeted treatment approach, is associated with a poor prognosis, and, in some studies, has an increased risk of LR This study validates that patients are younger, present with tumors of a higher grade and larger size, and present at a more advanced stage compared with non- patients. The study also validates that OS is worse among this group of patients. These findings are consistent with the current literature, which indicates that the triple-negative subtype is generally more aggressive, with worse prognosis overall.,16,17 Although breast cancer patients undergoing BCT have longterm outcomes equivalent to those of patients treated with mastectomy, significant debate remains regarding BCT as an appropriate treatment of. 8,18 Several investigators 1,19,2 26 JAMA Surgery March 214 Volume 149, Number 3 jamasurgery.com
6 Breast-Conserving Therapy for Original Investigation Research have reported results evaluating locoregional recurrence (LRR) related to the breast cancer subtype. Some studies 11,12,21 have included only patients who have undergone BCT, whereas others include patients who have undergone mastectomy. Rates for LR after BCT in these studies have ranged from 4% to 2% for patients compared with 3% to 14% for non- patients, suggesting higher LRR in patients. 19 Data regarding rates of LRR for patients are incongruent. Arvold et al 22 reviewed 1434 patients who underwent BCT and determined that 171 patients had a significantly higher risk of LR compared with patients with other subtypes (adjusted HR, 3.9; P =.1). A similar but smaller study by Nguyen et al 9 found that, of the 793 patients who underwent BCT, the patients had a dramatically increased risk for LR (adjusted HR, 7.1; P =.9). Additional studies 1-12,2,21 have demonstrated that the LRR rate after BCT was significantly greater in compared with the other subtypes. In contrast, Haffty et al 23 and Freedman et al 24 found no significant differences in LR rates for patients treated with BCT for vs non-. In the study by Haffty et al, patients had and 36 had non-, with no appreciable difference in -year breast relapse free survival between the 2 groups (83% vs 83%; differences were not significant). When comparing 73 patients who had received BCT by subtype, Freedmanetal 24 found no significant difference in LRR related to the subtypes (2.3% in ER- or PR-positive subtypes; 4.6% in ER- and PR-negative and ERBB2-positive subtypes, and 3.2% in ; P =.36). The present study validates that BCT is appropriate for patients with and supports the findings of Haffty et al, 23 Freedman et al, 24 and others 6 who have shown no increase in LRR for patients with. Our study is particularly relevant to widespread practice. The large numbers of surgeons in the US have different practice patterns, and a variety of adjuvant systemic therapies and radiotherapy are prescribed. Our study is particularly relevant to widespread practice because of the large number of US surgeons, each with different practice patterns, who treat these patients and the variety of standard adjuvant systemic therapies and radiotherapy that are prescribed widely in the United States. On multivariable analysis, after adjusting for tumor size and grade, no significant difference was found in risk of in-breast LR among subtypes. Indeed, few LRs were seen in any group. The use of adjuvant systemic chemotherapy may contribute to the low rate of LRR seen in this study because chemotherapy was routinely used for patients with no significant comorbidities. Furthermore, the only predictive variable for statistically significant risk of LR was a T3 tumor. This finding suggests that is not associated with increased risk for LR after BCT. Similarly, an increased risk for RR was not seen in patients but in patients with the ERBB2 subtype and stages II and III cancers. However, the multivariable analysis is of limited value with so few RR. Conclusions Triple-negative breast cancer is associated with worse OS and an increased risk for DR. However, this study validates the lack of a significant risk for LR in patients who undergo BCT. Despite the aggressive nature of, the triple-negative phenotype does not lead to a significantly increased risk of LRR compared with the non- phenotype in patients undergoing BCT. Breast-conserving therapy is appropriate for patients and should be routinely offered. ARTICLE INFORMATION Accepted for Publication: May 17, 213. Published Online: January 1, 214. doi:1.1/jamasurg Author Contributions: Drs Gangi and Giuliano had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Gangi, Giuliano. Acquisition of data: Gangi, Chung, Liou, Leong, Giuliano. Analysis and interpretation of data: Gangi, Chung, Mirocha, Giuliano. Drafting of the manuscript: Gangi, Chung, Mirocha. Critical revision of the manuscript for important intellectual content: Gangi, Chung, Mirocha, Liou, Giuliano. Statistical analysis: Gangi, Mirocha. Obtained funding: Giuliano. Administrative, technical, and material support: Giuliano. Study supervision: Chung, Giuliano. Conflict of Interest Disclosures: None reported. Funding/Support: This study was supported by the Fashion Footwear Charitable Foundation of New York, Inc, Associates for Breast and Prostate Cancer Studies, the Avon Foundation, the Margie and Robert E. Petersen Foundation, and Linda and Jim Lippman. Role of the Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Previous Presentation: This study was presented as a poster at the 84th Annual Meeting of the Pacific Coast Surgical Association; February 17, 213; Kauai, Hawaii, and is published after peer review and revision. REFERENCES 1. Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 29;16(1): Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 211;16(suppl 1): Sørlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 26;7:127. doi:1.1186/ Brenton JD, Aparicio SA, Caldas C. Molecular profiling of breast cancer: portraits but not physiognomy. Breast Cancer Res. 21;3(2):77-.. Rakha EA, Reis-Filho JS, Ellis IO. Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology. 28;7(2): Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 27;13(1, pt 1): Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 213;13(1): Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 22;347(16): Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 28;26(14): Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 211;128(3): jamasurgery.com JAMA Surgery March 214 Volume 149, Number 3 27
7 Research Original Investigation Breast-Conserving Therapy for 11. Zaky SS, Lund M, May KA, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol. 211;18(1): Meyers MO, Klauber-Demore N, Ollila DW, et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.ann Surg Oncol. 211;18(1): Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 21;363(2): Gabos Z, Thoms J, Ghosh S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 21;124(1): Zhang P, Xu BH, Ma F, et al. Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients [in Chinese]. Zhonghua Zhong Liu Za Zhi. 211;33(): Hattangadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 212;82(3): Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 27;9(1):R4. doi:1.1186/bcr Toft DJ, Cryns VL. Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 211;2(2): Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 212;133(3): Solin LJ, Hwang W-T, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer. 29;9(2): Montagna E, Bagnardi V, Rotmensz N, et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol.212;23(2): Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 211;29(29): Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 26;24(36): Freedman GM, Anderson PR, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation.cancer. 29;11(): JAMA Surgery March 214 Volume 149, Number 3 jamasurgery.com
The effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationClinical pathological and epidemiological study of triple negative breast cancer
International Journal of Research in Medical Sciences Ajay A et al. Int J Res Med Sci. 217 Jun;5(6):2657-2661 www.msjonline.org pissn 232-71 eissn 232-12 Original Research Article DOI: http://dx.doi.org/1.1823/232-12.ijrms2172465
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationApplicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery
Ann Surg Oncol (2015) 22:1128 1132 DOI 10.1245/s10434-014-4090-y ORIGINAL ARTICLE BREAST ONCOLOGY Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationLocoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
Breast Cancer Res Treat (2012) 133:831 841 DOI 10.1007/s10549-011-1891-6 REVIEW Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Aoife J. Lowery Malcolm R.
More informationSSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationLocal Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype
Local Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype Amr Ghannam 1, Omnia Abd el-fattah 1 and Ayman El-Nemr 2 1 Clinical Oncology
More informationWhat are Adequate Margins of Resection for Breast-Conserving Therapy?
What are Adequate Margins of Resection for Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School What are Adequate Margins
More informationRepeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates
Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the
More informationLipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study
BREAST of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study Steven J. Kronowitz, M.D. Cosman Camilo Mandujano, M.D. Jun Liu, M.D., Ph.D. Henry M. Kuerer,
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More information2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features
2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence
More informationTargeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center
Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic
More informationBreast Cancer Subtypes and the Risk of Local and Regional Relapse
VOLUME 28 NUMBER 10 APRIL 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Breast Cancer s and the Risk of Local and Regional Relapse K. David Voduc, Maggie C.U. Cheang, Scott Tyldesley,
More informationAre there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?
Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationPAPER. Long-term Outcome of Patients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer
ONLINE FIRST AER Long-term Outcome of atients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer Nimmi S. Kapoor, MD; Myung-Shin Sim, DrH; Jennifer Lin, MD; Armando
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationResection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland
Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery
More informationSupplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationRecurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction Aldona J. Spiegel, M.D., and Charles E. Butler, M.D. Houston, Texas Skin-sparing
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationEffects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes
Cancer Biol Med 2014;11:123-129. doi: 10.7497/j.issn.2095-3941.2014.02.007 ORIGINAL ARTICLE Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with
More informationPaget's Disease of the Breast: Clinical Analysis of 45 Patients
236 Paget's Disease of the Breast: Clinical Analysis of 45 Patients Mingfian Yang Hao Long Jiehua He Xi Wang Zeming Xie Department of Thoracic Oncology, Cancer Center of Sun Yat-sen University, Guangzhou
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationUnexpected features of breast cancer subtype
Liu et al. World Journal of Surgical Oncology (2015) 13:249 DOI 10.1186/s12957-015-0665-8 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Unexpected features of breast cancer subtype Ye-huan Liu,
More informationRESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India
APJCP.2016.17.6.2995 RESEARCH ARTICLE Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Dinesh Chandra Doval 1,2 *, P Suresh 1, Rupal Sinha 2, Saud Azam 2, Ullas Batra
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje
University of Groningen Local treatment in young breast cancer patients Joppe, Enje IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationOutcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer
DOI:10.22034/APJCP.2017.18.4.1151 Trastuzumab RESEARCH ARTICLE Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast
More informationPrediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath
DOI 10.1007/s00268-014-2752-3 BRIEF ORIGINAL SCIENTIFIC REPORT Prediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath E.
More informationTime to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study
Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective
More informationTreatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationClassifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology
2059 Classifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology New Primary Tumors Have More Favorable Outcomes than True Local Disease Recurrences Eugene Huang,
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationDifferences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: http://www.tandfonline.com/loi/ionc20 Differences in outcome for positive margins in a large cohort of breast cancer patients
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationEvaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy
Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Eun Yoon Cho, MD, PhD Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationSentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationComparison of clinical characteristics between occult and non-occult breast cancer
JBUON 2014; 19(3): 662-666 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Comparison of clinical characteristics between occult and non-occult
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationResearch Article Risk Factors of the Invasive Breast Cancer Locoregional Recurrence
BioMed Research International Volume 2015, Article ID 789646, 6 pages http://dx.doi.org/10.1155/2015/789646 Research Article Risk Factors of the Invasive Breast Cancer Locoregional Recurrence R. V. Liubota,
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationLandmarking, immortal time bias and. Dynamic prediction
Landmarking and immortal time bias Landmarking and dynamic prediction Discussion Landmarking, immortal time bias and dynamic prediction Department of Medical Statistics and Bioinformatics Leiden University
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationAt many centers in the United States and worldwide,
ORIGINAL ARTICLES A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram Julia Park, MS, Jane V.
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationRadiation Field Design and Patterns of Locoregional Recurrence Following Definitive Radiotherapy for Breast Cancer
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Breast Cancer Radiation Field Design and Patterns of Locoregional Recurrence Following Definitive
More information